Close Menu

Choices, Choices

At Motley Fool, Brian Orelli sizes up both Pacific Biosciences and Complete Genomics to determine which one is the "better buy." Orelli notes that some analysts are skeptical about sequencing's prospects, though he isn't since there is a demand for sequencing and because "the bust [is] still many years away." As for choosing between the two companies, Orelli says, "It's too early to make a definitive call, but of the two, I like PacBio better because I'

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports the US Food and Drug Administration has approved a treatment for a genetic disorder that causes rapid aging.

Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.

ScienceInsider reports Nature Communications is reviewing a paper on mentorship following social media criticism arguing it is sexist.

In PLOS this week: method to account for sequencing errors in phylogenies, study of influenza A in Switzerland, and more.